ISO 10993-17:2023 PDF

ISO 10993-17:2023 PDF

Name:
ISO 10993-17:2023 PDF

Published Date:
09/01/2023

Status:
Active

Description:

Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents

Publisher:
International Organization for Standardization

Document status:
Active

Format:
Electronic (PDF)

Delivery time:
10 minutes

Delivery time (for Russian version):
200 business days

SKU:

Choose Document Language:
$75
Need Help?
This document specifies the process and requirements for the toxicological risk assessment of medical device constituents. The methods and criteria used to assess whether exposure to a constituent is without appreciable harm are also specified. The toxicological risk assessment can be part of the biological evaluation of the final product, as described in ISO 10993-1.

The process described in this document applies to chemical characterization information obtained in line with ISO 10993-18. When a toxicological risk assessment of either the compositional information or analytical chemistry data (e.g. extractable data or leachable data) are required to determine whether the toxicological risks related to the constituents are negligible or tolerable.

The process described in this document is not intended to apply to circumstances where the toxicological risk has been estimated by other means, such as:
— constituents, excluding cohort of concern or excluded chemicals, that are present in or extracted from a medical device at an amount representative of patient exposure below a relevant, toxicologically-based reporting threshold (see applicable requirements in ISO 10993-18:2020, Annex E and ISO/TS 21726);
— a new or changed medical device for which chemical or biological equivalence has been established with an existing biocompatible or clinically established medical device (see applicable requirements in ISO 10993-18:2020, Annex C).

The process described in this document is also not applicable to:
— medical device constituents that do not contact the body (e.g. in vitro diagnostics);
— biological risks associated with physical interactions of the medical device with the body (i.e. application of mechanical forces, energy or surface morphology, etc.), provided that the chemical exposure is not changed;
— active pharmaceutical ingredients of device-drug combination products or biologic components of device-biologic combination products as additional regulatory considerations can apply;
— exposure to a particular constituent that arises from sources other than the device, such as food, water or air.
File Size : 1 file , 3.9 MB
Note : This product is unavailable in Ukraine, Russia, Belarus
Published : 09/01/2023

History

ISO 10993-17:2023
Published Date: 09/01/2023
Biological evaluation of medical devices - Part 17: Toxicological risk assessment of medical device constituents
$75
ISO 10993-17:2002
Published Date: 12/01/2002
Biological evaluation of medical devices - Part 17: Establishment of allowable limits for leachable substances
$47.1

Related products

ISO 10993-5:2009
Published Date: 06/01/2009
Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity
$58.2
ISO 10993-7:2008
Published Date: 10/15/2008
Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals
$83.4
ISO 10993-13:2010
Published Date: 06/15/2010
Biological evaluation of medical devices - Part 13: Identification and quantification of degradation products from polymeric medical devices
$37.2

Best-Selling Products